This article is part of Ophthalmology Advisor’s conference coverage from the 2021 meeting of American Society of Cataract and Refractive Surgery (ASCRS), held in Las Vegas from July 23 to 27, 2021. The team at Ophthalmology Advisor will be reporting on a variety of research presented by the cataract and refractive surgery experts at ASCRS. Check back for more from the ASCRS 2021 Meeting.

 

Surgeons reported a high level of satisfaction with sustained-release corticosteroid dexamethasone intraocular suspension 9% to control inflammation following cataract surgery. These findings were presented during the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting held July 23-27, 2021, in Las Vegas.

Data from patients (N=506) who underwent cataract surgery in March to December 2019 at 21 surgical sites were retrospectively collected. Surgeons were asked to report their satisfaction of sustained-release corticosteroid dexamethasone intraocular suspension 9% compared with other topical steroids and to report their perception of each patient’s satisfaction with the drug.


Continue Reading

A majority of surgeons (92%) reported they were ‘very satisfied’ or ‘satisfied’ with the sustained-release corticosteroid dexamethasone intraocular suspension 9%. Most surgeons (84%) indicated they were ‘very satisfied’ or ‘satisfied’ with the drug’s ease of use.

Compared with other topical steroids used for inflammation control after cataract surgery, the surgeons indicated they found the sustained-release corticosteroid dexamethasone intraocular suspension 9% to be ‘comparable’ (71%) or superior (28%) to the other products.

The surgeons recalled that 81% of their patients were ‘very satisfied’ or ‘satisfied’ with sustained-release corticosteroid dexamethasone.

This study was limited by not contacting the patients directly to assess their satisfaction, and instead relying on surgeons to retrospectively recall each patient’s experience during surgery and what the patient thought of the product. Additional studies are needed to confirm that patients were satisfied with sustained-release corticosteroid dexamethasone intraocular suspension 9%.

The study author concluded real-world data indicated that both surgeons and patients had a high level of satisfaction with inflammation control from sustained-release corticosteroid dexamethasone intraocular suspension 9% after cataract surgery. In addition, surgeons felt the product was easy to use and was either comparable or superior to other topical steroids.

Disclosure: The author declared affiliations with the biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures. 

Visit Ophthalmology Advisor’s conference section for complete coverage of the ASCRS 2021 meeting and more.

 

Reference

McCabe CM. Dexamethasone intraocular suspension 9% for post-cataract inflammation control: patient and surgeon satisfaction. Poster Presented at: 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting; July 2021; Las Vegas, NV. Poster 73591.